Based on 7 Wall Street analysts offering 12 month price targets for Genmab A/S in the last 3 months. The average price target is kr2,591.67 with a high forecast of kr2,800.00 and a low forecast of kr2,150.00. The average price target represents a 33.84% change from the last price of kr1,936.46.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"plus_tr_sans","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1906":"kr1,906","2801":"kr2,801","2129.75":"kr2,129.8","2353.5":"kr2,353.5","2577.25":"kr2,577.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2800,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n  <span style=\"color:#199ca5\">kr2.80K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2591.67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n  <span style=\"color:#828080\">kr2.59K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2150,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n  <span style=\"color:#912767\">kr2.15K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1906,2129.75,2353.5,2577.25,2801],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2023","6":"Oct<br/>2023","9":"Jan<br/>2024","12":"Apr<br/>2024","25":"Apr<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2049.31,2107.0553846153844,2164.800769230769,2222.5461538461536,2280.2915384615385,2338.036923076923,2395.7823076923078,2453.527692307692,2511.273076923077,2569.0184615384615,2626.7638461538463,2684.5092307692307,2742.254615384615,{"y":2800,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2049.31,2091.0299999999997,2132.75,2174.47,2216.19,2257.91,2299.63,2341.35,2383.07,2424.79,2466.51,2508.23,2549.9500000000003,{"y":2591.67,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2049.31,2057.0553846153844,2064.800769230769,2072.5461538461536,2080.2915384615385,2088.036923076923,2095.7823076923078,2103.527692307692,2111.273076923077,2119.0184615384615,2126.7638461538463,2134.5092307692307,2142.2546153846156,{"y":2150,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2779.53,"date":1682035200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2732.6,"date":1683244800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2722.34,"date":1685664000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2571,"date":1688688000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2554,"date":1691107200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2642.57,"date":1693526400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2480.42,"date":1696550400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1994.5,"date":1698969600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2158,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2165.43,"date":1704412800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1907.8,"date":1706832000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1950.62,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2049.31,"date":1712275200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Targetkr2,800

Average Price Targetkr2,592

Lowest Price Targetkr2,150

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

xxxxxxxxxxxxxxxxxx

Bank of America Securities

xxxxxxxxxxxxx

Reiterated

04/10/24

xxxxxxxxxxxxxxxxxx

UBS

xxxxxxxxxxxxx

Reiterated

04/03/24

xxxxxxxxxxxxxxxxxx

Citi

xxxxxxxxxxxxx

Assigned

03/21/24

xxxxxxxxxxxxxxxxxx

Jefferies

xxxxxxxxxxxxx

Reiterated

02/26/24

xxxxxxxxxxxxxxxxxx

Deutsche Bank

xxxxxxxxxxxxx

Reiterated

02/23/24

xxxxxxxxxxxxxxxxxx

Barclays

xxxxxxxxxxxxx

Assigned

02/23/24

xxxxxxxxxxxxxxxxxx

RBC Capital

xxxxxxxxxxxxx

Reiterated

02/21/24

xxxxxxxxxxxxxxxxxx

J.P. Morgan

xxxxxxxxxxxxx

Reiterated

12/05/23

xxxxxxxxxxxxxxxxxx

DNB Markets

xxxxxxxxxxxxx

Upgraded

11/08/23

xxxxxxxxxxxxxxxxxx

Goldman Sachs

xxxxxxxxxxxxx

Reiterated

09/28/23

Dominic Lunn

Credit Suisse

kr2800.00

Hold

44.59%

Upside

Reiterated

08/09/23

Credit Suisse Reiterates Neutral Rating on Genmab A/S (GEN:DC) (GMAB)Credit Suisse analyst Dominic Lunn reiterated a Neutral rating and DKK2,800.00 price target on Genmab A/S (GEN:DC) (NASDAQ: GMAB).

Rajesh Kumar

HSBC

kr3320.00

Buy

71.45%

Upside

Initiated

07/14/23

Genmab initiated with a Buy at HSBCGenmab initiated with a Buy at HSBC

James Quigley

Morgan Stanley

kr2235.00

Sell

15.42%

Upside

Initiated

05/12/23

Genmab initiated with an Underweight at Morgan StanleyGenmab initiated with an Underweight at Morgan Stanley

―

Exane BNP Paribas

―

Sell

―

Initiated

10/18/23

Genmab initiated with an Underperform at Exane BNP ParibasGenmab initiated with an Underperform at Exane BNP Paribas

Best Analysts Covering Genmab A/S

Which Analyst Should I Follow If I Want to Buy GB:0MGB and Sell After:

1 Month

Emmanuel PapadakisDeutsche Bank

Success Rate

9/12 ratings generated profit

Average Return

+2.48%

reiterated a buy rating 2 months ago

Copying Emmanuel Papadakis's trades and holding each position for 1 Month would result in 75.00% of your transactions generating a profit, with an average return of +2.48% per trade.

dummydummy

Success Rate

0/0 ratings generated profit

Average Return

0.00%

a rating ―

Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.

Premium Content

Find out which analyst has the highest Average Return & Success Rate

Go Premium

3 Months

Emily FieldBarclays

Success Rate

20/30 ratings generated profit

Average Return

+3.75%

assigned a buy rating 2 months ago

Copying Emily Field's trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +3.75% per trade.

dummydummy

Success Rate

0/0 ratings generated profit

Average Return

0.00%

a rating ―

Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.

Premium Content

Find out which analyst has the highest Average Return & Success Rate

Go Premium

1 Year

Emily FieldBarclays

Success Rate

18/30 ratings generated profit

Average Return

+19.18%

assigned a buy rating 2 months ago

Copying Emily Field's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of +19.18% per trade.

2 Years

Emmanuel PapadakisDeutsche Bank

Success Rate

9/12 ratings generated profit

Average Return

+15.88%

reiterated a buy rating 2 months ago

Copying Emmanuel Papadakis's trades and holding each position for 2 Years would result in 75.00% of your transactions generating a profit, with an average return of +15.88% per trade.

dummydummy

Success Rate

0/0 ratings generated profit

Average Return

0.00%

a rating ―

Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.

Premium Content

Find out which analyst has the highest Average Return & Success Rate

Go Premium

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0MGB Analyst Recommendation Trends

Rating

Dec 23

Jan 24

Feb 24

Mar 24

Apr 24

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 0MGB has received 11 Buy Ratings, 5 Hold Ratings, and 2 Sell Ratings. 0MGB average Analyst price target in the past 3 months is kr2,591.67.

Each month's total comprises the sum of three months' worth of ratings.

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxxxxxxxxxxxxxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

0MGB Financial Forecast

0MGB Earnings Forecast

Next quarter’s earnings estimate for 0MGB is kr12.00 with a range of kr3.42 to kr33.27. The previous quarter’s EPS was kr9.66. 0MGB beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 39.22% of the time in the same period. In the last calendar year 0MGB has Outperformed its overall industry.

0MGB Sales Forecast

Next quarter’s sales forecast for 0MGB is kr3.96B with a range of kr3.53B to kr4.81B. The previous quarter’s sales results were kr4.68B. 0MGB beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 45.57% of the time in the same period. In the last calendar year 0MGB has Outperformed its overall industry.

0MGB Stock Forecast FAQ

What is GB:0MGB’s average 12-month price target, according to analysts?

Based on analyst ratings, Genmab A/S’s 12-month average price target is kr2,591.67.

What is GB:0MGB’s upside potential, based on the analysts’ average price target?

Genmab A/S has 33.84% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Genmab A/S a Buy, Sell or Hold?

Genmab A/S has a conensus rating of Moderate Buy, which is based on 4 buy ratings, 2 hold ratings and 1 sell ratings.

What is Genmab A/S’s share price target?

The average share price target for Genmab A/S is kr2,591.67. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is kr2,800.00 ,and the lowest forecast is kr2,150.00. The average share price target represents 33.84% Increase from the current price of kr1,936.455.

What do analysts say about Genmab A/S?

Genmab A/S’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 7 Wall Streets Analysts.

How can I buy shares of Genmab A/S?

To buy shares of GB:0MGB, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Genmab A/S (0MGB) Share Forecast & Price Target

0MGB Analyst Ratings

0MGB Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Genmab A/S

0MGB Analyst Recommendation Trends

0MGB Financial Forecast

0MGB Earnings Forecast

0MGB Sales Forecast

0MGB Stock Forecast FAQ

Get More with TipRanks Premium

Detailed List of Analyst Forecasts